




Revista Portuguesa de
Cardiologia
Portuguese Journal of **Cardiology**

www.revportcardiol.org



ORIGINAL ARTICLE

Anti-thrombotic and glucose lowering therapy in diabetic patients with coronary artery disease undergoing PCI with stent implantation: A prospective multicenter observational study on prescription patterns and clinical outcomes. Baseline inclusion data of the ARTHEMIS registry

Sérgio Bravo Baptista^{a,b,1}, Gustavo Pires de Moraes^c, Luís Almeida Moraes^d, João Costa^e, Hugo Vinhas^f, Gustavo Campos^g, Pedro Carrilho Ferreira^h, Nélson Valeⁱ, Filipe Seixo^j, Miguel Santos^a, Cristina Martins^k, Diogo Rodrigues Brás^l, André Alexandre^m, Luís Raposo^{i,*1}

^a Hospital Prof. Dr. Fernando Fonseca, E.P.E./Hospital Amadora Sintra, Portugal

^b Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), CAML, Faculdade de Medicina, Universidade de Lisboa, Portugal

^c Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E., Portugal

^d Centro Hospitalar Universitário de Lisboa Central, E.P.E./Hospital de Santa Marta, Portugal

^e Hospital de Braga E.P.E., Portugal

^f Centro Hospitalar e Universitário do Algarve, E.P.E./Hospital de Faro, Portugal

^g Centro Hospitalar e Universitário de Coimbra, E.P.E./Hospitais da Universidade de Coimbra, Portugal

^h Centro Hospitalar Universitário de Lisboa Norte, E.P.E./Hospital de Santa Maria, Portugal

ⁱ Centro Hospitalar Universitário de Lisboa Ocidental, E.P.E./Hospital de Santa Cruz, Portugal

^j Centro Hospitalar de Setúbal, E.P.E./Hospital de São Bernardo, Portugal

^k Hospital Garcia de Orta, E.P.E., Portugal

^l Hospital do Espírito Santo E.P.E., Évora, Portugal

^m Centro Hospitalar Universitário do Porto, E.P.E./Hospital Geral de Santo António, Portugal

Received 31 August 2024; accepted 23 March 2025

KEYWORDS

Diabetes;
PCI;
Stent;
Anti-platelet therapy;
Glucose lowering
drugs

Abstract

Introduction and objectives: Diabetes is a major determinant of ischemic events after percutaneous coronary intervention (PCI). In a nationwide prospective registry, antiplatelet and glucose-lowering treatment regimens, and two-year clinical outcomes were studied in unselected patients with type 2 diabetes undergoing coronary stent implantation. The current analysis describes the population's baseline characteristics and the prescription patterns of anti-thrombotic and glucose-lowering drugs.

* Corresponding author.

E-mail address: lfor.md@gmail.com (L. Raposo).

¹ These authors equally contributed.

<https://doi.org/10.1016/j.repc.2025.03.006>

0870-2551/© 2025 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

S. Bravo Baptista, G. Pires de Moraes, L. Almeida Moraes et al.

Methods: Between January and November 2021, 1000 patients were enrolled in 12 Portuguese hospitals. In addition to clinical and procedural-related variables, thrombotic (DAPT score) and bleeding risks (PRECISE DAPT) were estimated, and medication (including planned duration of dual antiplatelet therapy) were recorded.

Results: Inclusion rate was relatively high (68.6%) among all eligible patients during the study period (mean age 68 ± 10 years-old, and 70% of male gender). The indication for PCI was an acute coronary syndrome in 58% of cases and 63% had 2–3 vessel coronary artery disease (SYNTAX score 15.6 ± 10.7 ; mean stent length and diameter 26.3 ± 14.8 and 3.0 ± 1.2 mm, respectively). Of patients not on oral anticoagulation, only 49.8% received potent P2Y12 inhibitors; overall recommendation for shorter DAPT regimens (<6 months,) was 26.5% and did not differ according to low vs. high bleeding risk (24.6% vs. 29.7%; $p < 0.125$). In those also under anticoagulation, 62.6% received a recommendation for <30-day regimens, or no DAPT at all (13.6%). Prolonged DAPT (>12 months) was planned at baseline in 0.7% of the whole cohort and 1.2% of ACS patients. PCI complexity (but not CAD extent) was associated with DAPT duration. Self-reported duration of diabetes was >6 years in 57% (HbA1c $7.6 \pm 1.7\%$) and 12% had known microangiopathy at inclusion. SGLT2 inhibitors (28%) and GLP-1 analogues (3%) were used seldom at admission.

Conclusions: Standard six-to-12-month antiplatelet regimens were the most widely used, largely with acetylsalicylic acid and clopidogrel. DAPT duration was mostly related to PCI complexity and oral-anticoagulation. Metabolic control was off-target and guideline-directed treatment for diabetes was underused at admission (clinicaltrials.gov NCT04481997).

© 2025 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALAVRAS CHAVE

Diabetes;
Angioplastia;
Stent;
Anti-agregantes
plaquetares;
Terapêutica
hipoglicemiante

Terapêutica anti-trombótica e hipoglicemiante em doentes diabéticos com doença arterial coronária submetidos a ICP com implantação de stent: um estudo prospectivo multicêntrico observacional sobre padrões de prescrição e resultados clínicos. Dados basais de inclusão do registo ARTHEMIS

Resumo

Introdução e objetivos: A diabetes é um dos principais determinantes do risco isquémico após intervenção coronária percutânea (ICP). Os regimes de terapêutica anti-plaquetar e hipoglicemiante em doentes diabéticos submetidos a angioplastia com implantação de stent, assim como o prognóstico aos 2 anos, foram estudados num registo prospectivo multicêntrico de âmbito nacional. Presente análise reporta os resultados referentes às características basais dos doentes incluídos e aos padrões de prescrição.

Métodos: Entre janeiro e novembro de 2021 foram recrutados 1000 doentes em doze hospitais portugueses. Para além das variáveis clínicas, angiográficas e relacionadas com o procedimento, foram especificamente estimados os riscos trombótico e hemorrágico, através dos cálculos dos scores DAPT e PRECISE-DAPT, respetivamente, e registadas as recomendações respeitantes à terapêutica farmacológica, incluindo o esquema proposto de dupla anti-agregação e a sua duração planeada.

Resultados: Considerando toda a população elegível durante o período do estudo, a taxa de inclusão (68,6%) foi elevada (idade média 68 ± 10 anos e 70% dos participantes do género masculino). A indicação para ICP foi uma síndrome coronária aguda em 58% dos casos e 63% tinham doença multivaso (Score SYNTAX score $15,6 \pm 10,7$; comprimento e diâmetro médios dos stents implantados de $26,3 \pm 14,8$ e $3,0 \pm 1$ mm, respetivamente). Entre os doentes sem terapêutica anti-coagulante oral concomitante, apenas 49,8% receberam indicação para inibidores potentes do receptor P2Y12 e os regimes de curta duração (<6 meses) de terapêutica anti-plaquetar dupla foram recomendados em 26,5%, sem diferenças de acordo com o risco hemorrágico avaliado pelo score PRECISE-DAPT (24,6% versus 29,7%, nos doentes de risco baixo versus elevado, respetivamente; $p < 0,125$). Naqueles sob anti-coagulação oral, 62,6% tiveram indicação para regimes <30 dias, ou apenas terapêutica anti-coagulante (13,6%). Anti-agregação dupla prolongada (>12 meses) foi planeada em apenas 0,7% de todos os casos e em 1,2% dos doentes tratados no contexto de SCA. A complexidade da intervenção, mas não a extensão da doença coronária, associou-se a duração da terapêutica anti-plaquetar. A duração da diabetes foi reportada em >6 anos por 57% dos doentes (HbA1c $7,6 \pm 1,7\%$) e 12% apresentavam complicações microangiopáticas no momento da inclusão. A utilização de fármacos modificadores do prognóstico como os inibidores da SGLT2 (28%) e dos análogos da GLP-1(3%) foi relativamente baixa na admissão.

Conclusões: Regimes de dupla anti-agregação com duração entre os 6 e os 12 meses e baseados principalmente em AAS e clopidogrel foram os mais utilizados. A duração da terapêutica anti-plaquetar dupla relacionou-se essencialmente com a complexidade da intervenção e com a anti-coagulação oral. O controlo metabólico registado na inclusão foi subóptimo na população estudada, tal como a utilização de medicação anti-diabética presentemente recomenda (Clinicaltrials.gov NCT04481997).

© 2025 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Diabetes is a major determinant of clinical outcomes in patients with clinically overt coronary artery disease (CAD).¹⁻⁴ In the setting of percutaneous coronary intervention (PCI), factors such as disease complexity and the inherently higher risk of progressive atherosclerosis and future ischemic events (including revascularization failure),^{5,6} should be considered when tailoring antithrombotic regimens and disease-modifying drug therapy. Concordantly, diabetes weighs in several risk scores that aim at estimating post-PCI thrombotic risk – such as the DAPT score⁷ – and clinicians are compelled by current recommendations to integrate these calculations (together with bleeding risk) into management decisions concerning the duration of dual antiplatelet therapy.⁸ Also, and importantly, in recent years, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) analogues have been shown to further reduce cardiovascular morbidity and mortality in patients with diabetes and coronary disease,⁹⁻¹¹ which was a major breakthrough in the pharmacological management of diabetes.

The uptake of current guidelines in everyday practice may however be hampered by several hurdles, such as the external validity of randomized trials that support guidelines, as well as financial and logistical constraints, especially in certain socio-economic scenarios. As a result, significant variability in treatment prescriptions may exist, which is largely unknown. Accordingly, to further address these gaps, a prospective nationwide observational study was undertaken.

Objectives

The study main objectives were to (1) describe the clinical characteristics of an unselected consecutive population of patients with DM undergoing PCI with stent implantation; (2) determine the anti-thrombotic regimens prescribed, regarding drugs of choice, prescribed dosage, indicated and actual duration of treatment, their main determinants and adherence, and (3) evaluate the prescription patterns of guideline-directed drug therapy for diabetes at baseline and during follow-up. Also, the incidence of major ischemic and hemorrhagic events at two years was assessed.

This paper describes the baseline inclusion data and drug prescription regimens.

Methods

Study design and oversight

The anti-thrombotic and glucose lowering therapy in diabetic patients with coronary artery disease undergoing PCI: a prospective multicenter observational study on drug use and implications for clinical outcomes (ARTHEMIS) study, was an investigator-initiated nationwide prospective observational study, implemented at 12 medium-to-high volume PCI-capable hospitals in Portugal. A detailed description of the clinical endpoints and their definitions is provided in the [Supplemental Materials](#).

Baseline data was collected at the time of inclusion in a dedicated e-CRF. The study was planned and reported according to the STROBE statement for reporting observational studies.¹² An external contract research organization ensured the quality and reliability of the data, through regular monitoring.

Patient population

All consecutive patients with type-2 diabetes undergoing PCI with stent implantation performed in at least one major coronary artery in the context of stable CAD or an acute coronary syndrome were screened and invited to participate. Inclusion could be considered at any time between PCI and hospital discharge. Other than balloon-only PCI, short life expectancy due to significant comorbidity (according to the opinion of the attending physician), type 1 diabetes and unwillingness to participate, no major exclusions existed. Inclusion and exclusion criteria are detailed in the online [Supplemental Material](#).

Study procedures and definitions

For screening and inclusion purposes, the diagnosis of type-2 diabetes was adjudicated as self-reported when already known at the time of hospital admission, and according to the 2021 criteria of the American Diabetes Association when newly diagnosed or confirmation was warranted.¹³ Ischemic and bleeding risks were estimated by the DAPT⁷ and PRECISE-DAPT Risk Scores.¹⁴

After screening, patients were treated according to local practice; PCI technique was left to the discretion of the operator, as well as subsequent medical management. The indication for PCI was reported by the local investiga-




Figure 1 Flowchart of patient inclusion (for details, see [Supplemental Figure 1](#)).

tors and was not centrally adjudicated. As per-protocol, DAPT regimen had to be specifically indicated, including the drugs prescribed and specific planned duration. If available (according to local clinical practice in each hospital), HbA1c was registered at the index admission and at each visit.

Sample size and statistical analysis

Taking the sample size of previously published studies that evaluated different strategies of DAPT duration as reference, we arbitrarily estimated that the inclusion of 1000 consecutive patients would allow for a detailed characterization of the diabetic population with CAD and the evaluation of ischemic, heart failure and hemorrhagic events throughout the two-year follow-up.

Results are reported as percentages (for dichotomous variables) and as means and standard-deviation or median and interquartile range for continuous variables, as appropriate. Normality was assessed by the Kolmogorov-Smirnov test and by visual inspection of histograms and Q-Q plots. When necessary, comparisons were performed using the χ^2 test (with Yates correction when appropriate) for categorical variables, the Student t test, the Satterthwaite test or 1-way ANOVA for continuous variables with normal distribution or the Kruskal-Wallis test for continuous variables with a non-normal distribution. When appropriate, 95% confidence intervals were calculated. Two-tailed tests of significance are reported. For all comparisons, a p-value of <0.05 was considered statistically significant. Statistical analysis was performed with IBM SPSS software version 23 (SPSS Inc, Chicago, IL).

Ethics and regulation

The study was undertaken according to good clinical practices and all patients provided written informed consent.

The protocol complies with the Declaration of Helsinki and was approved by institutional review boards at each participating site. The study was registered with the Portuguese National Data Protection Committee and on ClinicalTrials.gov (identifier: NCT04481997).

Funding and sponsorship

The study was sponsored by the Association for Research and Development of the Faculty of Medicine (AIDFM) – Cardiovascular Center of the University of Lisboa (CCUL) and had the scientific sponsorship of the Portuguese Association of Cardiovascular Intervention (APIC). It was funded as an investigator-initiated study, by an unrestricted grant from AstraZeneca (ESR-19-20188). Study coordinators and local investigation teams were fully responsible for protocol preparation, patient selection, study compliance, and data entry and analysis.

Results

Patient inclusion

Between January and November 2022, 6557 PCI procedures were performed in the 12 participating centers, of which 2056 (31.4%) were reportedly in patients with diabetes. From the 1457 who were eligible (meeting all inclusion/exclusion criteria), 1000 were included in the study at the time of the procedure (68.6%). Of these, four were subsequently excluded because a diagnosis of diabetes was not confirmed. Of the remaining 996 patients, five died during the index hospital admission and were excluded from the analysis ([Figure 1](#)). Overall average inclusion rate was 111 patients/month. A description of inclusion rates per each participating hospital is detailed in [Supplemental Material \(Supplemental Figure 2 and Supplemental Table 1\)](#).

Table 1 Baseline characteristics – epidemiological data and previous history.

Patients included	996
Age (mean \pm SD)	68.3 \pm 10.1
Male gender, n (%)	700 (70.3)
BMI (mean \pm SD)	28.6 \pm 4.7
Cardiovascular risk factors	
Smoking	
Current, n (%)	168 (16.9)
Previous, n (%)	273 (27.4)
Total, n (%)	441 (44.3)
Hypertension, n (%)	883 (89.2)
Hyperlipidaemia, n (%)	831 (84.5)
Diabetes history	
Time of diagnosis	
Index admission, n (%)	36 (3.6)
<1 year, n (%)	51 (5.1)
2–5 years, n (%)	153 (15.4)
6–10 years, n (%)	154 (15.5)
>10 years, n (%)	412 (41.4)
Unknown, n (%)	190 (19.0)
Microvascular complications	
Yes, n (%)	121 (12.1)
No, n (%)	514 (51.6)
Unknown, n (%)	361 (36.2)
Cardiovascular history	
Coronary disease	
Previous myocardial infarction, n (%)	277/974 (28.4)
Previous revascularization, n (%)	318/986 (32.3)
Previous hospitalization for heart failure, n (%)	78/952 (8.2)
Atrial fibrillation, n (%)	107/981 (10.9)
Prosthetic heart valve, n (%)	14/988 (1.4)
Previous stroke/TIA, n (%)	93/976 (9.5)
Symptomatic peripheral artery disease, n (%)	104/902 (11.5)
Previous bleeding (BARC 2 or 3)	24/940 (2.6)
Previous oncologic disease, n (%)	91/968 (9.4)
Other serious medical conditions, n (%)	63/996 (6.3)
Left ventricular ejection fraction	
Unknown	76 (7.6%)
<30%	59 (5.9%)
30–40%	146 (14.7%)
41–50%	153 (15.4%)
>50%	562 (56.4%)
Mean value (\pm SD)	49.0 \pm 12.2

Population baseline characteristics**Clinical and procedural characteristics**

The mean age was 68 ± 10 years-old and 70.3% of participants were male. The prevalence of classical risk factors was very high, with more than 4/5 of all patients reporting hypertension or dyslipidemia, and almost half active or past history of smoking. Also, roughly one third had clinically overt CAD (28.4% previous acute myocardial infarction and 32.3% a prior revascularization event), while mean LVEF

Table 2 Baseline characteristics – coronary disease and coronary intervention.

Indication for angiography (n=996)	
Chronic coronary syndrome, n (%)	420 (42.1)
nST acute coronary syndrome, n (%)	374 (37.6)
ST elevation acute myocardial infarction, n (%)	202 (20.3)
Coronary artery disease	
Number of vessels with disease (n=996)	
1 vessel, n (%)	368 (36.9)
2 vessels, n (%)	334 (33.6)
3 vessels, n (%)	294 (29.5)
Multivessel disease, n (%)	628 (63.1)
Syntax score (n=919) (mean \pm SD)	15.6 \pm 10.7
Percutaneous coronary intervention	
Number of treated lesions per patient (n=993)	
1 lesion, n (%)	705 (71.0)
2 lesions, n (%)	215 (21.7)
≥3 lesions, n (%)	73 (7.3)
Number of stents per patient (n=993)	
1 stent (%)	614 (61.8)
2 stents, n (%)	250 (25.2)
≥3 stents, n (%)	129 (13.0)
Mean number of stents per-patient	1.57
Mean number of stents per-lesion	1.14
Total stent length ([mm]; mean \pm SD)	26.3 \pm 14.8
Stent diameter	
<3.0 mm, n (%)	705 (45.0)
3.0 mm, n (%)	423 (27.0)
>3.0 mm, n (%)	431 (28.0)
Stent diameter ([mm]; mean \pm SD)	3.0 \pm 1.2

was $49 \pm 12\%$, and 8.2% reported at least one prior admission due to heart failure. Baseline characteristics are detailed in Table 1.

Most patients underwent PCI in the setting of an ACS (20.3% ST elevation myocardial infarction and 37.6% NSTE-ACS) and 63.1% had multivessel CAD, with a mean SYNTAX score of 15.6 ± 10.7 . Despite disease extent, most patients (71%) had only one lesion treated with stent implantation. The mean number of stents per-lesion and per-patient was 1.14 and 1.57, respectively; 45% of implanted stents had a diameter <3.0 mm (mean 3.0 ± 1.2 mm) and mean stent length was 26.3 ± 14.8 mm (Table 2).

Ischemic and bleeding risks

A DAPT score of 2 or greater – indicating a high ischemic risk – was present in 546 (56.9%) of the 962 patients for whom all variables were available for calculation. Likewise, the PRECISE-DAPT score was >25 (indicating a high bleeding risk) in 389 out of 970 (39.3%) (Figure 2). The distribution and relationship between ischemic and bleeding scores are shown in Figure 3 and Supplemental Figure 3. Notably, although high ischemic risk was significantly more frequent in ACS vs. stable patients (67.9% vs. 40.8%, $p < 0.001$), the proportion of patients with high bleeding risk was roughly similar in either subgroup (38.7% vs. 41.1%, $p = 0.29$).




Figure 2 Ischemic (DAPT) and bleeding (PRECISE-DAPT) risk scores.

Antithrombotic therapy at admission and hospital discharge

Remarkably, 33.8% of patients were not on any anti-thrombotic treatment at the time of hospital admission – the majority of whom were ACS patients (83.1%) – while 15.9% were already on dual antiplatelet therapy (DAPT) ([Supplemental Figure 4](#)). At hospital discharge, DAPT was prescribed to 99.9% of patients without concomitant anti-coagulation and to 84.5% of patients also treated with anticoagulants ([Figure 4](#) and [Supplemental Table 2](#)). Among the former group potent P2Y12 inhibitors (ticagrelor and prasugrel) were used in only 417/836 (49.8%) ([Supplemental Table 2](#)), although, as expected, the proportion was still much higher in patients with ACS as compared to chronic coronary syndromes (CCS) (74.7% vs. 16.1%; $p<0.001$).

The overall proportion of patients with ACS not receiving new-generation P2Y12 antagonists was 36.3%. These patients were older (71 ± 10 vs. 65 ± 10 years old; $p<0.001$), had lower body mass index (28.2 ± 4.3 vs. 29.2 ± 5.0 kg/m²; $p=0.007$), lower creatinine clearance (68.9 ± 31.5 ml/m² vs 93.4 ± 41.8 ml/min; $p<0.001$), were more likely to have atrial fibrillation (25% vs. 1%; $p<0.001$) or any indication for anti-coagulation (41.3% vs. 1.4%; $p<0.001$), all translating into an higher bleeding risk as assessed by the PRECISE-DAPT score (26.7 ± 13.5 vs. 17.9 ± 12.0 ; $p<0.001$). Prior history of BARC 2 or 3 bleeding, and gender were not associated with the likelihood of potent P2Y12 inhibitor prescription. Conversely, 13.6% of patients treated in the setting of chronic coronary syndrome did receive DAPT with ticagrelor or prasugrel.

Planned duration of antithrombotic therapy

In the cohort of patients without concomitant anticoagulation, recommendation for shorter DAPT regimens (≤ 6 months) or no DAPT was 26.5% and did not differ significantly according to bleeding risk (24.6% vs. 29.7% in low vs. high-bleeding risk as defined by a PRECISE-DAPT score >25 ;




Figure 3 Distribution and relationship of ischemic (DAPT) and bleeding (PRECISE-DAPT) risk scores.

$p=0.125$). In patients with chronic coronary syndromes, recommended DAPT durations of 6 and 12 months were 55.2% and 44.4%, respectively, while in those treated in the setting of an ACS, 12 months were the standard indication (93.6%). Prolonged DAPT (≥ 12 months, irrespectively of the initial indication for the PCI) was planned in only 0.7% of patients ([Figure 4](#) and [Supplemental Table 3](#)).

When the duration of DAPT was evaluated according to clinical setting, and considering “regular” a DAPT duration of 6 or 12 months; “short-term” a DAPT duration of <6 or <12 months; and “long-term” a DAPT duration of >6 or >12 months, respectively for CCS and ACS patients, shorter durations were infrequently planned but still more likely to be prescribed in high bleeding-risk patients (6.5% vs. 2.5%, $p=0.038$), and longer durations were more preva-




Figure 4 Antithrombotic treatment at discharge and planned DAPT duration.

lent in high ischemic risk patients (24.0% vs. 15.9%, p=0.015) ([Supplemental Table 4](#)). Still, prolonged DAPT was initially planned at discharge in only 1.2% of ACS patients with a potential indication ([Supplemental Table 5](#)).

Furthermore, age and gender did not influence planned DAPT duration, nor did the complexity of coronary disease, as assessed by the Syntax score, the presence of multivessel disease or the number of lesions ([Supplemental Table 4](#)). On the other hand, longer DAPT duration was planned more often in patients with previous myocardial infarction (29.8% vs. 15.1%, p<0.001), prior revascularization (29.9% vs. 14.3%, p<0.001) and also in cases with more complex procedures (defined by higher number of implanted stents and longer total stent length) ([Supplemental Table 4](#)). This observation was consistent for both chronic disease and ACS ([Supplemental Tables 5 and 6](#)).

Of note, in all participants also on oral anticoagulants, at least one antiplatelet agent was added, and triple therapy (DAPT+anticoagulant) was prescribed in 134/155 (86.5%) of these patients ([supplemental Table 2](#)). In almost all cases (128/134, 95.5%), the preferred DAPT regimen was aspirin and clopidogrel.

Diabetes staging and characterization

Self-reported duration of DM was longer than five years in 57% of participants, 12% had known microangiopathic involvement at inclusion, and 3.6% were newly diagnosed during the index admission ([Table 1](#)). Mean hemoglobin A1c and fasting glucose levels were $7.6 \pm 1.7\%$ and $164 \pm 66\text{ mg/dl}$, respectively. Microangiopathic involvement at inclusion was known in 12% of patients.

Notably, only 28% and 3% of patients were taking SGLT2 inhibitors and GLP-1 analogues on admission, respectively, a proportion that increased significantly for the former (51%), but not for the latter (4%) at discharge ([Supplemental Figure 5](#)).

Discussion

To the best of our knowledge, this is the first study to specifically characterize prospectively a contemporary population of patients with type-2 diabetes and concomitant obstructive CAD undergoing stent implantation, in terms of clinical and cardiovascular risk profiles, as well as the most common approaches to pharmacological management. Our main findings can be summarized as follows: (1) both ischemic and bleeding risks were relatively high, as assessed by the DAPT and PRECISE-DAPT risk scores; (2) PCI complexity, but not CAD extent, was associated with DAPT duration; (3) the adherence to single antiplatelet regimens from inception in high bleeding risk patients was relatively low; and (4) metabolic control was off-target and guideline-directed treatment for diabetes was underused at hospital admission, although it improved at discharge.

Representative real-world data

Registry data provides an opportunistic snapshot on how results of randomized trials are translated to everyday practice through guideline uptake. Our registry has the virtue of including centers across the entire country, encompass-

ing a wide range of socio-economic and logistic scenarios thus enabling a solid representation of the real world. Importantly, the information concerning almost 70% of all eligible patients has been captured, although the main reason for non-inclusion was unclear (operator decision or not reported). Interestingly though, baseline characteristics of our patients are remarkably similar to those of patients with diabetes included in the THEMIS (ticagrelor in patients with stable coronary disease and diabetes) randomized trial, except for a lower incidence of prior revascularization and lower ejection fraction.¹⁵

Antithrombotic and antiplatelet regimens

It is noteworthy that despite the high-risk profile of our population, over 1/3 of patients were not on any antithrombotic treatment by the time of hospital admission. These patients were less likely to have classical risk factors (such as hypertension and high cholesterol, but not smoking history), clinically overt vascular disease, prior admissions due to heart failure and atrial fibrillation, but there were no differences concerning gender and age.

At hospital discharge, the overall adherence to current recommendations in both chronic coronary syndrome and ACS patients seemed to be quite straightforward, although a significant proportion of patients with ACS were not discharged on a new P2Y12 inhibitor. These patients were older and had a higher bleeding risk, although recent guidelines do not in fact encourage this approach.¹⁶ On the other hand, PCI complexity was the main modulator of total prescribed DAPT duration. Trials assessing prolonged DAPT regimens have not been stratified by CAD complexity at baseline, just after PCI, and the DAPT score was developed in patients that have completed a standard duration regimen without events.⁷ Still, variables related to procedural risk and complexity have some weight in the score and a post-hoc patient-level metaanalysis of randomized trials showed a significant interaction between the benefits of prolonged DAPT duration and PCI complexity.¹⁷

DAPT regimens and bleeding risk

Trials performed in patients at high risk of bleeding undergoing PCI have suggested that short DAPT regimens are safe, whether or not on a background of direct oral anticoagulants. Despite individual trials have been formally underpowered to specifically assess between-group differences regarding thrombotic events (such as stent thrombosis), safety has been confirmed in large series and metaanalysis.^{18,19} Operators have seemingly welcomed these findings as demonstrated by the high adoption of short protocols (<6 months) particularly in patients with a concomitant indication for anticoagulation, but also – although to a lesser extent – in those with high PRECISE-DAPT score and no-anticoagulation. Ongoing follow-up will further inform on clinical outcomes of these strategies on a real word setting.

Glucose-lowering therapy

Guidelines recommend a HbA1c<7% as a metabolic control target in patients with diabetes and CAD.²⁰ Although glycemic levels are associated with cardiovascular outcomes, the most widely used drugs for diabetes for decades – namely metformin, sulfonylureas and dipeptidyl-peptidase-4 inhibitors – have either not been specifically tested or have failed to consistently reduce ischemic events and mortality, despite improving glucose levels.^{11,21} Recently, SGLT2 inhibitors and GLP-1 analogues have gained preponderance as guideline-recommended first line therapy, driven by significantly improvements in cardiovascular morbidity and mortality, even in patients without overt diabetes.^{20,22} Although in our cohort, mean HbA1c was within range of prior randomized trials performed in patients with DM and known CAD,^{15,23} optimal metabolic control rates (Hb A1c<7%) were worse than those reported both in the first diabetes prevalence study in Portugal (PREVADIAB study)²⁴ and in the First National Health Examination Survey – INSEF 2015²⁵ (41% vs. 69% and 63%, respectively). This discrepancy most likely stems from differences in the targeted patients, given that the aforementioned surveys were aimed at studying broader populations with known and unknown diabetes, rather than selected individuals with clinically overt atherosclerotic disease, inherently more likely to have advanced diabetes and poorer metabolic control. Still, less than one third of patients were taking SGLT2 inhibitors by the time of hospital admission, and the proportion of those medicated with GLP-1 analogues was marginal. Despite the improvement at hospital discharge, prescription rates, especially for SGLT2 inhibitors, were still suboptimal. Altogether, this may be a reflection of some unwarranted perception of low tolerability to the drug in the real-life setting, impaired awareness of potential benefits by clinicians, worries about a low absolute benefit at the individual patient level, and, not less importantly, cost constraints.

Limitations

Our work has the inherent limitations of observational studies. It is not possible to reliably measure the potential impact of the Hawthorne effect and its influence on prescription patterns. Considering that the calculation of risk scores (both hemorrhagic and ischemic) may not always be routine practice, it is possible that their knowledge by operators and/or attending physicians may have induced some behavioral change, by increasing the chance of changing standard DAPT duration (as compared to empirical clinical judgment alone).

Despite recommendations being made to include all consecutive cases meeting study criteria, over one third of eligible patients were not enrolled, mostly for unknown reasons. As data on this group was not systematically collected, it is not possible to firmly assess any potential biases resulting from inadvertent selection. Still, as previously mentioned, the baseline characteristics of our population

are similar to other studies focusing on the same patient subset, which is reassuring of the external validity of our study.

Finally, for most variables including the diagnosis and duration of diabetes, investigators relied on self-reported data. Nevertheless, although confirmation of diabetes by laboratory testing was not protocol-mandated, only a minority of patients were excluded because of unconfirmed diabetes.

Conclusions

In this real-world population of patients with type-2 diabetes and obstructive CAD undergoing PCI with stent implantation, both ischemic and bleeding risks were relatively high, as assessed by the DAPT and PRECISE-DAPT scores. Recommendations for DAPT duration were mostly in line with current guidelines. Clinical setting (ACS vs. CCS), the need for concomitant oral anticoagulation and PCI complexity (but not CAD extent) were the main correlates of DAPT duration. Average metabolic control was off-target and guideline-directed treatment for diabetes was underused at baseline visit, although it improved by the time of hospital discharge.

Ethical approval

The protocol complies with the Declaration of Helsinki and was approved by institutional review boards at each participating site.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgments

The authors would like to acknowledge the CRO CETERA team (Inês Zimbarra Cabrita, Susana Silva and Carolina Rodrigues) for the implementation and management of the study in Portugal.

Appendix A. Supplementary data

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.repc.2025.03.006>.

References

1. Sattar N, Rawshani A, Franzén S, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. *Circulation*. 2019;139:2228–37.
2. Cavender MA, Steg PG, Smith SC, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death. *Circulation*. 2015;132:923–31.
3. Mak K-H, Vidal-Petiot E, Young R, et al. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. *Eur J Prev Cardiol*. 2022;28: 1795–806.
4. Krempf M, Parhofer KG, Steg PG, et al. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). *Am J Cardiol*. 2010;105:667–71.
5. Farkouh ME, Domanski M, Dangas GD, et al. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM follow-on study. *J Am Coll Cardiol*. 2019;73:629–38.
6. Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet*. 2018;391.
7. Yeh RW, Secemsky EA, Kerejakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *JAMA*. 2016;315:1735.
8. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J*. 2019;40:87–165.
9. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. *JAMA Cardiol*. 2021;6:148.
10. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol*. 2021;9:653–62.
11. Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes a systematic review and meta-analysis. *JAMA*. 2018;319:1580–91.
12. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med*. 2007;4:e296.
13. American Diabates Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes – 2021. *Diabetes Care*. 2021;44 Supplement_1:S15–33.
14. Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet*. 2017;389:1025–34.
15. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. *N Engl J Med*. 2019;381:1309–20.
16. Task A, Members F, Byrne RA, et al. 2023 ESC guidelines for the management of acute coronary syndromes developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC) (United Kingdom), Takeshi Kimura (Japan). *Eur Heart J*. 2023;44:3720–826.
17. Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. *J Am Coll Cardiol*. 2016;68:1851–64.
18. Valgimigli M, Spirito A, Sartori S, et al. 1- or 3-month DAPT in patients with HBR with or without oral anticoagulant therapy after PCI. *JACC Cardiovasc Interv*. 2023;16:2498–510.
19. Benenati S, Galli M, De Marzo V, et al. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. *Eur Hear J Cardiovasc Pharmacother*. 2021;7:86–93.

S. Bravo Baptista, G. Pires de Moraes, L. Almeida Moraes et al.

20. Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. *Eur Heart J.* 2023;44:4043–140.
21. Li CX, Liang S, Gao L, et al. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. *PLoS One.* 2021;16:1–15.
22. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med.* 2023;389:2221–32.
23. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multi-vessel revascularization in patients with diabetes. *N Engl J Med.* 2012;367:2375–84.
24. Gardete-Correia L, Boavida JM, Raposo JF, et al. First diabetes prevalence study in Portugal: PREVADIAB study. *Diabet Med.* 2010;27:879–81.
25. Barreto M, Kislaya I, Gaio V, et al. Prevalence, awareness, treatment and control of diabetes in Portugal: results from the first National Health examination Survey (INSEF 2015). *Diabetes Res Clin Pract.* 2018;140:271–8.